REMDESIVIR

N/A

Manufactured by Gilead Sciences, Inc.

20,319 FDA adverse event reports analyzed

Last updated: 2026-04-14

About REMDESIVIR

REMDESIVIR is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Gilead Sciences, Inc.. The most commonly reported adverse reactions for REMDESIVIR include OFF LABEL USE, ALANINE AMINOTRANSFERASE INCREASED, COVID-19, DRUG INEFFECTIVE, DEATH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for REMDESIVIR.

Top Adverse Reactions

OFF LABEL USE2,208 reports
ALANINE AMINOTRANSFERASE INCREASED933 reports
COVID 19896 reports
DRUG INEFFECTIVE762 reports
DEATH751 reports
BRADYCARDIA651 reports
ASPARTATE AMINOTRANSFERASE INCREASED627 reports
ACUTE KIDNEY INJURY622 reports
RESPIRATORY FAILURE526 reports
COVID 19 PNEUMONIA480 reports
LIVER FUNCTION TEST INCREASED420 reports
CONDITION AGGRAVATED378 reports
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION328 reports
PNEUMONIA325 reports
BLOOD CREATININE INCREASED320 reports
CARDIAC ARREST286 reports
RENAL IMPAIRMENT279 reports
HYPOTENSION278 reports
SEPTIC SHOCK272 reports
DYSPNOEA257 reports
HYPOXIA257 reports
MULTIPLE ORGAN DYSFUNCTION SYNDROME230 reports
DRUG INTERACTION221 reports
MATERNAL EXPOSURE DURING PREGNANCY215 reports
PRODUCT USE IN UNAPPROVED INDICATION209 reports
OXYGEN SATURATION DECREASED206 reports
THERAPY CESSATION205 reports
BRONCHOPULMONARY ASPERGILLOSIS202 reports
ACUTE RESPIRATORY DISTRESS SYNDROME186 reports
PYREXIA183 reports
SEPSIS179 reports
TRANSAMINASES INCREASED178 reports
RENAL FAILURE167 reports
ACUTE RESPIRATORY FAILURE165 reports
NO ADVERSE EVENT159 reports
HEPATIC ENZYME INCREASED147 reports
FOETAL EXPOSURE DURING PREGNANCY143 reports
INFUSION SITE EXTRAVASATION136 reports
EXPOSURE DURING PREGNANCY131 reports
SINUS BRADYCARDIA129 reports
PRODUCT USE ISSUE126 reports
PULMONARY EMBOLISM126 reports
INFUSION RELATED REACTION124 reports
PNEUMOTHORAX124 reports
GENERAL PHYSICAL HEALTH DETERIORATION121 reports
PNEUMONIA BACTERIAL120 reports
PREMATURE DELIVERY120 reports
ATRIAL FIBRILLATION113 reports
GLOMERULAR FILTRATION RATE DECREASED113 reports
HEPATIC FUNCTION ABNORMAL108 reports
PREMATURE BABY108 reports
ELECTROCARDIOGRAM QT PROLONGED106 reports
THROMBOCYTOPENIA105 reports
INTENTIONAL PRODUCT USE ISSUE104 reports
NAUSEA104 reports
THERAPY INTERRUPTED102 reports
SHOCK97 reports
INTERNATIONAL NORMALISED RATIO INCREASED94 reports
DISEASE PROGRESSION92 reports
RASH92 reports
SARS COV 2 TEST POSITIVE91 reports
CARDIO RESPIRATORY ARREST90 reports
TACHYCARDIA86 reports
HEART RATE DECREASED84 reports
MUCORMYCOSIS84 reports
ASPERGILLUS INFECTION83 reports
DIARRHOEA83 reports
PRODUCT PREPARATION ERROR83 reports
HYPERTENSION81 reports
COUGH79 reports
DRUG INDUCED LIVER INJURY77 reports
THERAPY NON RESPONDER77 reports
DISSEMINATED INTRAVASCULAR COAGULATION75 reports
RESPIRATORY DISTRESS74 reports
PULSELESS ELECTRICAL ACTIVITY73 reports
HYPERGLYCAEMIA72 reports
LEUKOPENIA72 reports
LIVER INJURY72 reports
BLOOD BILIRUBIN INCREASED71 reports
HYPERTRANSAMINASAEMIA71 reports
PNEUMONIA ASPIRATION71 reports
VOMITING71 reports
BLOOD ALKALINE PHOSPHATASE INCREASED70 reports
METABOLIC ACIDOSIS70 reports
STAPHYLOCOCCAL INFECTION70 reports
CHILLS69 reports
GASTROINTESTINAL HAEMORRHAGE69 reports
RESPIRATORY DISORDER67 reports
ASTHENIA65 reports
PNEUMOMEDIASTINUM64 reports
ANAEMIA63 reports
NEUTROPENIA63 reports
BLOOD PRESSURE DECREASED62 reports
HYPERKALAEMIA62 reports
RECALLED PRODUCT ADMINISTERED62 reports
CHEST PAIN60 reports
FATIGUE60 reports
HAEMOGLOBIN DECREASED59 reports
LIVER DISORDER59 reports
PAIN59 reports

Report Outcomes

Out of 13,113 classified reports for REMDESIVIR:

Serious 83.9%Non-Serious 16.1%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male7,235 (59.7%)
Female4,881 (40.3%)
Unknown2 (0.0%)

Reports by Age

Age 64298 reports
Age 69292 reports
Age 70272 reports
Age 71267 reports
Age 75262 reports
Age 73261 reports
Age 63255 reports
Age 65254 reports
Age 62248 reports
Age 68241 reports
Age 79231 reports
Age 66230 reports
Age 59229 reports
Age 67228 reports
Age 72226 reports
Age 60220 reports
Age 77219 reports
Age 74214 reports
Age 61213 reports
Age 76202 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with REMDESIVIR?

This profile reflects 20,319 FDA FAERS reports that mention REMDESIVIR. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for REMDESIVIR?

Frequently reported terms in FAERS include OFF LABEL USE, ALANINE AMINOTRANSFERASE INCREASED, COVID-19, DRUG INEFFECTIVE, DEATH, BRADYCARDIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures REMDESIVIR?

Labeling and FAERS entries often list Gilead Sciences, Inc. in connection with REMDESIVIR. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.